| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
TPCK targets serine proteases, particularly chymotrypsin and related enzymes. It acts as an irreversible inhibitor by alkylating the active site histidine residue of the enzyme. The chloromethyl ketone moiety reacts covalently with the histidine residue, resulting in irreversible enzyme inactivation. It is used to study protease function and inhibition mechanisms.
|
|---|---|
| ln Vitro |
In vitro, TPCK has been demonstrated to irreversibly inhibit chymotrypsin and related serine proteases. It is widely used in biochemical research to study protease function and to inhibit proteolytic activity in cell lysates and protein preparations. The compound shows specificity for chymotrypsin-like proteases.
|
| ln Vivo |
In vivo activity data are limited. TPCK is primarily used as a research tool for in vitro studies. It is not used as a therapeutic agent. Its irreversible inhibition mechanism and potential toxicity limit its in vivo applications. It may be used in preclinical studies to investigate protease function.
|
| Enzyme Assay |
For enzyme inhibition assays, TPCK is dissolved in DMSO or appropriate organic solvent and diluted in assay buffer. The target protease is incubated with varying concentrations of TPCK (0.1-100 µM) at 25-37°C for 15-60 minutes. Residual enzyme activity is measured using chromogenic or fluorogenic substrates. Inhibition kinetics and IC₅₀ values are calculated.
|
| Cell Assay |
For cell-based studies, cells are cultured in DMEM or RPMI-1640 with 10% FBS at 37°C in 5% CO₂. Cells are treated with TPCK at 1-100 µM for 1-24 hours. Protease inhibition is assessed by measuring enzyme activity in cell lysates. Cellular effects are assessed using appropriate assays including viability, apoptosis, and protein expression analysis.
|
| Animal Protocol |
TPCK is not typically used for in vivo animal studies as a therapeutic agent. It may be used in preclinical studies to investigate the role of serine proteases in disease models. For such studies, it is formulated in suitable vehicles and administered to rodents. Efficacy and toxicity are monitored.
|
| ADME/Pharmacokinetics |
TPCK has a molecular weight of 351.85 g/mol and a molecular formula of C₁₇H₁₈ClNO₃S. It appears as a white to off-white solid powder. It has a PubChem CID of 9824. It is soluble in DMSO and other organic solvents. Storage: at -20°C.
|
| Toxicity/Toxicokinetics |
Acute toxicity: TPCK is a reactive alkylating agent and should be handled with extreme care. It may cause skin, eye, and respiratory irritation. It is potentially toxic and may be mutagenic. Standard laboratory safety practices should be followed. Proper personal protective equipment should be used.
|
| Additional Infomation |
TPCK is an irreversible inhibitor of chymotrypsin-like serine proteases. It is widely used in biochemical research to study protease function and to inhibit proteolytic activity. It is a research reagent and is not an FDA-approved drug.
|
| Molecular Formula |
C17H18CLNO3S
|
|---|---|
| Molecular Weight |
351.8
|
| Exact Mass |
351.07
|
| CAS # |
329-30-6
|
| PubChem CID |
9824
|
| Appearance |
White to off-white solid powder
|
| Density |
1.277g/cm3
|
| Boiling Point |
509.9ºC at 760mmHg
|
| Melting Point |
106-108ºC(lit.)
|
| Flash Point |
262.2ºC
|
| LogP |
4.164
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
23
|
| Complexity |
475
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC=C(C=C1)S(=O)(=O)NC(CC2=CC=CC=C2)C(=O)CCl
|
| InChi Key |
MQUQNUAYKLCRME-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H18ClNO3S/c1-13-7-9-15(10-8-13)23(21,22)19-16(17(20)12-18)11-14-5-3-2-4-6-14/h2-10,16,19H,11-12H2,1H3
|
| Chemical Name |
N-(4-chloro-3-oxo-1-phenylbutan-2-yl)-4-methylbenzenesulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8425 mL | 14.2126 mL | 28.4252 mL | |
| 5 mM | 0.5685 mL | 2.8425 mL | 5.6850 mL | |
| 10 mM | 0.2843 mL | 1.4213 mL | 2.8425 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
